Ashling Wahner

Read our recap of the top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

Lurbinectedin plus atezolizumab received CHMP recommendation as first-line maintenance for ES-SCLC that has not progressed following induction therapy.

The EMA's CHMP recommends marketing authorization for tarlatamab monotherapy for ES-SCLC following relapse during or after platinum-based chemotherapy.

Neoadjuvant T-DXd followed by THP has received conditional approval in China for the treatment of patients with HER2-positive stage II/III breast cancer.

The PI3Kα inhibitor risovalisib has been approved in Japan for PIK3CA-mutated ovarian clear cell carcinoma after progression on chemotherapy.

Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.

Megan Kruse, MD, discusses the use of imaging modalities in breast cancer management and emphasizes the role of FES-PET/CT in identifying ER presence.

The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated stage III or IV classical Hodgkin lymphoma.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

First-line sacituzumab govitecan plus pembrolizumab generated efficacy and safety improvements vs chemotherapy plus pembrolizumab in PD-L1–positive mTNBC.

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.

The NCCN guidelines endorse frontline sacituzumab govitecan alone for PD-L1–negative mTNBC and in combination with pembrolizumab for PD-L1–positive mTNBC.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

Key experts across oncology specialties share how they prioritize patient safety in their practices related to AE awareness and mitigation strategies.

Response to evorpacept plus zanidatamab was predicted by high levels of CD47 expression in patients with HER2-positive metastatic breast cancer.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

Treatment with subcutaneous amivantamab plus pembrolizumab was deemed effective and safe in patients with recurrent or metastatic, PD-L1–positive HNSCC.

Igor Makhlin, MD, notes the imaging modalities used in metastatic breast cancer and highlights FES-PET/CT as a specific modality for ER-positive disease.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The bispecific ADC iza-bren elicited PFS and OS benefits compared with chemotherapy in pretreated, unresectable, locally advanced or metastatic TNBC.

Sophia O’Brien, MD, discusses the role of nuclear medicine in lobular breast cancer diagnosis and staging, as well as use criteria for FES-PET/CT.

Will the FDA approve giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy?

Subcutaneous amivantamab monotherapy received breakthrough therapy designation from the FDA for recurrent or metastatic, HPV-unrelated HNSCC.

Martha Welman, MD, discusses the value of personalized patient relationships over technology, especially for populations with limited access to resources.

The FDA has approved acalabrutinib plus venetoclax for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.